How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Pre and Post Vacuum Class B Autoclaves Market
- By Autoclave Type: Pre Vacuum Autoclaves, Post Vacuum Autoclaves, Combined Pre and Post Vacuum Autoclaves
- By Chamber Size: Small (up to 75 liters), Medium (76 to 150 liters), Large (151 to 300 liters), Extra Large (above 300 liters)
- By Application: Healthcare and Hospitals, Pharmaceutical Industry, Laboratories and Research Centers, Veterinary Clinics, Tattoo and Beauty Studios
- By Automation Level: Manual Operation, Semi-Automatic Operation, Fully Automatic Operation
- By Sterilization Cycle Type: Standard Gravity Cycle, Pre-Vacuum Cycle, Post-Vacuum Cycle, Liquid Cycle
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Pre Vacuum Autoclaves leads By Autoclave Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 291 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.176 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.184 →
Full report · locked preview
Everything inside the Pre and Post Vacuum Class B Autoclaves Market report
A complete, evidence-based study - 12 chapters and 122 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Autoclave Type 3
Chamber Size 4
Application 5
Automation Level 3
Sterilization Cycle Type 4
Companies profiled
Getinge AB
Tuttnauer
Systec GmbH
Steris Corporation
Belimed AG
MELAG Medizintechnik GmbH & Co. KG
Astell Scientific Ltd.
Priorclave Ltd.
Hirayama Manufacturing Corporation
MMM Group (Miele & Cie. KG)
Lancer Corporation
Pelton & Crane
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Getinge AB
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Tuttnauer
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Systec GmbH
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Steris Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Belimed AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →MELAG Medizintechnik GmbH & Co. KG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Astell Scientific Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Priorclave Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Hirayama Manufacturing Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →MMM Group (Miele & Cie. KG)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Lancer Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Pelton & Crane
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →SciCan Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Anprolene (Andersen Products)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Yamato Scientific Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$3,168M by 2033 · 8.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Pre Vacuum Autoclaves73.4
- Post Vacuum Autoclaves15.3
- Combined Pre and Post Vacuum Autoclaves11.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$547.0M → $1,091M · 9.0%
Europe$381.3M → $689.8M · 7.7%
Asia Pacific$348.1M → $688.0M · 8.9%
Latin America$215.5M → $425.0M · 8.9%
Middle East and Africa$165.8M → $322.5M · 8.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.372026
8.402027
8.422028
8.432029
8.442030
8.442031
8.472032
8.472033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Getinge AB26.1
- Tuttnauer15.1
- Systec GmbH7.4
- Steris Corporation10.4
- Belimed AG8.4
- MELAG Medizintechnik GmbH & Co. KG4.6
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Autoclave Type10.5%
Chamber Size21.5%
Application25.9%
Automation Level30.2%
Sterilization Cycle Type11.8%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.9
- Europe21.4
- Asia Pacific21.4
- Latin America13.2
- Middle East and Africa10.0
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Getinge AB | 78 | 82 | 90 | 94 | 73 | 77 | 82 |
| Tuttnauer | 83 | 86 | 68 | 68 | 78 | 69 | 75 |
| Systec GmbH | 87 | 79 | 82 | 86 | 81 | 80 | 83 |
| Steris Corporation | 57 | 74 | 63 | 67 | 70 | 70 | 67 |
| Belimed AG | 53 | 63 | 67 | 55 | 62 | 66 | 61 |
| MELAG Medizintechnik GmbH & Co. KG | 46 | 49 | 70 | 47 | 68 | 70 | 58 |
| Astell Scientific Ltd. | 61 | 65 | 59 | 54 | 63 | 55 | 60 |
| Priorclave Ltd. | 56 | 48 | 48 | 46 | 50 | 44 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Getinge AB
- Tuttnauer
- Systec GmbH
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Getinge AB | ◐ | ◐ | ✓ | ✓ | ✓ | ◐ |
| Tuttnauer | ◐ | ✓ | − | − | ◐ | − |
| Systec GmbH | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Steris Corporation | ◐ | ✓ | − | ◐ | ◐ | − |
| Belimed AG | ◐ | − | ✓ | ◐ | − | ✓ |
| MELAG Medizintechnik GmbH & Co. KG | − | − | ◐ | − | ◐ | ◐ |
| Astell Scientific Ltd. | ◐ | − | − | − | − | ◐ |
| Priorclave Ltd. | − | ◐ | ◐ | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Systec GmbH83
2Getinge AB82
3Tuttnauer75
4Steris Corporation67
5Belimed AG61
6Astell Scientific Ltd.60
7MELAG Medizintechnik GmbH & Co. KG58
8Priorclave Ltd.49
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Getinge ABSystec GmbH
Challenger2
Strong scale, closing on the leaders.
TuttnauerSteris Corporation
Contender3
Focused players with pockets of strength.
Belimed AGMELAG Medizintechnik GmbH & Co. KGAstell Scientific Ltd.
Niche1
Specialists in a single segment or region.
Priorclave Ltd.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Autoclave Type in North America, then scale across Pre and Post Vacuum Class B Autoclaves Market — a $664M beachhead inside a $11.6B market.
Beachhead (SOM)$664Mobtainable near-term
Serviceable (SAM)$4.63Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion86 fit
Pre Vacuum Autoclaves
Best fit — highest urgency & budget in Autoclave Type.
Economic buyer76 fit
Post Vacuum Autoclaves
Strong fit — clear ROI and a fast path to value.
End user67 fit
Combined Pre and Post Vacuum Autoclaves
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Autoclave Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Chamber Size & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel27%
Digital / self-serve20%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Autoclave Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Pre and Post Vacuum Class B Autoclaves Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified43%
Sales qualified20%
Evaluation11%
Closed-won7%
$8.6KCAC
$45KLTV
5.2:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Pre and Post Vacuum Class B Autoclaves Market is a durable-growth opportunity — $4.63B by 2033, compounding at 8.7%.
TAM · 2025$2.37Btoday
TAM · 2033$4.63Bforecast
CAGR8.7%2027–2033
Cumulative$30.5Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.63BTotal addressable market
SAM$1.81BServiceable available market
SOM$349MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.7% CAGR
Demand compounds through 2033, outpacing GDP across Autoclave Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Autoclave Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.63BLarge & growingTAM by 2033 at 8.7% CAGR
$1.81BServiceable nowreachable with today’s model
$349MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.61BBear5.7% CAGR
$4.63BBase8.7% CAGR
$5.93BBull11.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Chamber Size optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Pre and Post Vacuum Class B Autoclaves Market — a $1.17B market by 2033. Plan: grow share from 8.0% to 16.8%.
Market size · 2033$1.17Btotal addressable
Market CAGR6.6%2027–2033
Target share16.8%from 8.0% today
Revenue ambition$196Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.0% | 16.8% | Ahead |
| Revenue | $101M | $196M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 35.6% | 42.5% | Behind |
| Customer retention | 84.8% | 93.8% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Autoclave Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Chamber Size capability
A defensible second engine — invest in Chamber Size to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Autoclave Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Chamber Size
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $28M capacity & capability investment
- Greenlight bolt-on M&A in Chamber Size
- Authorise North America expansion plan
- Fund R&D program for Autoclave Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeAhead
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Pre and Post Vacuum Class B Autoclaves Market conversation — a $8.31B market you can size, segment and defend in minutes.
Market size · 2033$8.31Btotal opportunity
Growth5.2%CAGR to 2033
Addressable buyers1,679+accounts in scope
Typical ROI4.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Autoclave Type
Goal Grow share in Autoclave Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.6×return on cost, year one
< 3 mopayback period
$78K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Getinge ABTuttnauerSystec GmbHSteris CorporationBelimed AGMELAG Medizintechnik GmbH & Co. KGAstell Scientific Ltd.Priorclave Ltd.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Pre and Post Vacuum Class B Autoclaves Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Pre and Post Vacuum Class B Autoclaves Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Prealigners Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportPRC1 Antibody Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportPraziquantel Market
Market size, share, segmentation and regional forecast.
$950M market · 2025 base year
View reportPravastatin Sodium Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportPravastatin Sodium API Market
Market size, share, segmentation and regional forecast.
$999M market · 2025 base year
View reportPrasugrel Hydrochloride Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportPrasugrel HCl API Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportPranoprofen Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportPranoprofen Eye Drops Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportPranoprofen API Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportPranlukast Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportPramoxine Market
Market size, share, segmentation and regional forecast.
$982M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.